

ICM Research in Progress Seminar

Monday 15th October

Yi Yang

(Dr. K Marchbank)

Testing the efficacy of new anti-complement therapies in murine models of kidney diseases

We aim to test the ability of a range of existing and novel complement therapeutics which block complement cascade progression to “treat” atypical haemolytic uraemic syndrome (aHUS) and C3 glomerulopathy (C3G) using mouse models.

Philip Brown

(Prof. J Isaacs, Dr. A Pratt)

Investigation of methotrexate metabolites in CD4+ T-Lymphocytes as a predictor of response to treatment in Rheumatoid Arthritis

Biomarkers to guide treatment decisions are needed to maximise the outcomes for patients with Rheumatoid Arthritis (RA). This project seeks to determine the kinetics of metabolites of Methotrexate (a key drug in RA treatment), combined with an exploration of its mechanisms of action to develop a biomarker for treatment response.

Rong Ou

(Prof. A Mellor)

Critical Mechanisms in Treg activation during Murine leukemia virus infection

Murine leukemia infection causes acquired immune deficiency. A critical feature in immune suppression is hyper activation of Treg. Here we will discuss the role of B cells and CD40 in Treg activation during an active MuLV infection and how an infection may be controlled by combining host resistant factors and reduced Treg activation.

Chair: Stella Breininger

MED L2.4, 2nd Floor William Leech Building

1pm - 2pm